Alzheimer’s Disease-Related Dementia e-Newsletter : Program Description

Early identification and assessment of Alzheimer’s disease (AD) and mild cognitive impairment (MCI) are critical to improving the outlook for patients. Neuropsychological testing can be useful in diagnosing MCI and in tracking symptom evolution. Although no medications currently are available to prevent or cure AD, cholinesterase inhibitors and memantine have been shown to forestall deterioration. Various strategies are being investigated as mechanisms to alter the neurobiological substrates of AD. A number of biomarkers are also being evaluated for their potential in identifying and tracking the progression of AD, and in developing disease-modifying therapies. Use of biomarkers in addition to standardized assessment tests may help improve diagnostic accuracy. This media-rich e-Newsletter contains actual clinical commentaries from physician experts on improving identification and management of early-stage AD and MCI. It also includes graphics, brain images, and other visual elements illustrating the pathophysiology and clinical course of MCI and AD, compiled from various authoritative sources.